Search results for "Highlights"

Results 31 - 40 of about 166 for "Highlights".
Sort by: Relevance | Newest | Oldest

Infliximab or tofacitinib for IBD associated with lower response to COVID-19 vaccination

An industry-funded study in England looked at SARS-CoV-2 antibody concentrations after two vaccine doses among patients taking infliximab, tofacitinib, thiopurine, ustekinumab, or vedolizumab for inflammatory bowel disease (IBD), comparing them to healthy controls.
25 Feb 2022

Spotlight on Digestive Disease Week

Highlights from the conference, held this past week in San Diego, included new research and clinical tips on stopping Barrett's esophagus surveillance, diet and environmental risk factors in patients with inflammatory bowel disease, and new research on proton-pump inhibitors.
24 May 2019

Specialty groups offer updated guidelines on care surrounding bariatric surgery

The update from endocrinology, obesity, surgery, anesthesiology, and nutrition experts covers perioperative nutritional, metabolic, and nonsurgical support of patients undergoing bariatric procedures.
22 Nov 2019

PPIs not associated with mortality risk for most causes, study finds

While patients who took proton-pump inhibitors (PPIs) had significantly higher risks of all-cause mortality and mortality due to cancer, cardiovascular diseases, respiratory diseases, and digestive diseases, lag times of up to six years attenuated these associations so they were no longer statistically significant.
22 Jul 2022

Patients with mild acute diverticulitis can be safely treated without antibiotics in outpatient setting

Patients who presented to an ED and were randomized to receive only anti-inflammatory and symptomatic treatment had similar rates of hospitalization, return to the ED, and pain control as those who received the usual antibiotic treatment, a Spanish trial found.
19 Nov 2021

Review finds upadacitinib most effective for moderate to severe ulcerative colitis remission

The systematic review and meta-analysis of biologic and small-molecule drugs for patients with moderate to severe ulcerative colitis also found that upadacitinib ranked highest for adverse events, whereas vedolizumab had the lowest rate of adverse events and serious adverse events.
17 Dec 2021

Bentonite hemostatic powder noninferior to standard care for GI bleeding

In a single-blind randomized controlled trial, bleeding was controlled within 30 days in 90.1% of adults with acute nonvariceal bleeding on upper GI endoscopy assigned to receive TC-325 versus 81.4% of those assigned to standard treatment.
17 Dec 2021

AGA releases new guidance on coagulation disorders in patients with cirrhosis

A clinical practice guideline from the American Gastroenterological Association (AGA) suggested against extensive preprocedural testing in patients with stable cirrhosis who are undergoing routine GI procedures, among other recommendations.
19 Nov 2021

Boxed warning added to liver disease drug

The drug has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis, which increases the risk of serious liver injury, the FDA said.
23 Feb 2018

PPI prophylaxis didn't affect 90-day mortality rates among ICU patients

Gastrointestinal bleeds were less common among at-risk ICU patients who received IV pantoprazole instead of placebo, but rates of clinically important events were similar overall.
26 Oct 2018

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next